QDEL icon

QuidelOrtho

29.31 USD
-0.27
0.91%
Updated May 22, 11:53 AM EDT
1 day
-0.91%
5 days
-11.40%
1 month
19.83%
3 months
-30.15%
6 months
-26.98%
Year to date
-34.92%
1 year
-31.20%
5 years
-83.11%
10 years
34.20%
 

About: QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

Employees: 6,600

0
Funds holding %
of 7,245 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 87

19% more call options, than puts

Call options by funds: $13.7M | Put options by funds: $11.6M

1.69% more ownership

Funds ownership: 108.95% [Q4 2024] → 110.64% (+1.69%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]

4% less funds holding

Funds holding: 272 [Q4 2024] → 260 (-12) [Q1 2025]

18% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 39

20% less capital invested

Capital invested by funds: $3.26B [Q4 2024] → $2.61B (-$658M) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$25
15%
downside
Avg. target
$33
11%
upside
High target
$44
50%
upside

3 analyst ratings

positive
33%
neutral
33%
negative
33%
UBS
Lu Li
1%downside
$29
Neutral
Maintained
8 May 2025
Jefferies
Tycho Peterson
50%upside
$44
Buy
Upgraded
8 May 2025
JP Morgan
Casey Woodring
15%downside
$25
Underweight
Maintained
21 Apr 2025

Financial journalist opinion

Based on 12 articles about QDEL published over the past 30 days

Neutral
Zacks Investment Research
1 day ago
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL continues to witness growth on the back of its strong product portfolio.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Positive
Zacks Investment Research
1 week ago
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Neutral
Seeking Alpha
1 week ago
QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)
Despite a once promising future, QuidelOrtho Corporation's current prospects are unappealing. I rated QuidelOrtho as a "Buy" in July 2023, but the stock has since declined by ~60% as its growth has stagnated. On 05/07/2025 the company reported top and bottom-line beats for its Q1/2025 earnings, bumping its shares up >40%.
QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)
Positive
Zacks Investment Research
1 week ago
QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand
Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025.
QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand
Neutral
Seeking Alpha
2 weeks ago
QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Conor McNamara - RBC Capital Patrick Donnelly - Citi Andrew Brackmann - William Blair Jack Meehan - Nephron Research Lu Li - UBS Casey Woodring - JPMorgan Andrew Cooper - Raymond James Tycho Peterson - Jefferies Operator Welcome to the QuidelOrtho First Quarter 2025 Financial Results Conference Call and Webcast. At this time, all participant lines are in listen mode only.
QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript
Positive
Zacks Investment Research
2 weeks ago
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates
QuidelOrtho (QDEL) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.44 per share a year ago.
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates
Neutral
Business Wire
2 weeks ago
QuidelOrtho Reports First Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 30, 2025. “We delivered solid first quarter performance driven by growth in our Labs business and the strength of our recurring revenue business model,” said Brian J. Blaser, President an.
QuidelOrtho Reports First Quarter 2025 Financial Results
Neutral
Zacks Investment Research
2 weeks ago
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
Positive
Zacks Investment Research
3 weeks ago
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
Positive
Zacks Investment Research
3 weeks ago
QuidelOrtho (QDEL) Earnings Expected to Grow: Should You Buy?
QuidelOrtho (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QuidelOrtho (QDEL) Earnings Expected to Grow: Should You Buy?
Charts implemented using Lightweight Charts™